Healthcare / Medical DevicesIstanbul
$298.00
-0.75 (-0.25%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 19%
FCF escenarios
weak_data · normalized FCF $2.8M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
55/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7.1B
P/E
156.0x
↑EV/EBITDA
43.0x
↑ROE
12.4%
↑Gross Margin
45.1%
↓Debt/Equity
0.21
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+34.3%
FCF CAGR
-53.1%
FCF margin
0.4%
FCF / Net income
0.05x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $709.1M · net income $50.4M · FCF $2.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $709.1M | $709.1M | $490.2M | $347.2M | $292.9M |
| Net Income | $50.4M | $50.4M | $-77.4M | $-115.2M | $-20.8M |
| EBITDA | $166.2M | $166.2M | $48.6M | $-65.0M | $39.0M |
| EPS | 2.10 | 2.10 | -3.20 | -4.80 | -0.87 |
| Gross Margin | 45.1% | 45.1% | 37.0% | 14.9% | 34.4% |
| Operating Margin | 22.5% | 22.5% | 2.5% | -23.6% | 12.0% |
| Net Margin | 7.1% | 7.1% | -15.8% | -33.2% | -7.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.21 | 0.21 | 0.17 | 0.27 | 0.10 |
| Current Ratio | 2.25 | 2.25 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $2.8M | $2.8M | $81.0M | $-82.5M | $26.7M |
| Returns | |||||
| ROE | 12.4% | 12.4% | -21.6% | -34.4% | -9.3% |
| Valuation | |||||
| P/E | 156.02 | 156.02 | — | — | — |
| EV/EBITDA | 43.01 | 43.01 | 52.55 | — | 14.31 |
| P/B | 17.46 | 17.46 | 7.11 | 11.98 | 2.48 |
| Growth & Yield | |||||
| Revenue Growth | 44.7% | 44.7% | 41.2% | 18.5% | — |
| EPS Growth | 165.6% | 165.6% | 33.3% | -451.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
132.6%
EPS terminal req.
$26.44
Spread vs growth
33.0%
5Y implied EPS CAGR
72.4%
EPS terminal req.
$32.00
Spread vs growth
93.2%
10Y implied EPS CAGR
37.7%
EPS terminal req.
$51.53
Spread vs growth
127.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+259.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-3.20 → 2.10
Residual
+259.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.